Company*
(Country; Symbol)

Company*
(Country; Symbol)

Product

Terms/Details (Date)


Active Biotech AB* (Sweden)

Strathmann Biotec AG (Germany; unit of Strathmann AG)

Deal for manufacturing of Active Biotech's TTS CD3, which is being developed for non-small-cell lung cancer

Strathmann also will help in development of the product under the long-term deal, and could get money from any milestones and royalties the product generates; Biovitrum previously was the manufacturer (6/3)

Biovitrum AB* (Sweden)

Maxygen Inc. (MAXY)

Bivitrum will manufacture Maxygen's interferon-beta for Phase I and Phase II trials

Terms of the deal were not disclosed (6/8)

Cell Signaling Technology Inc.*

Li-Cor Biosciences Inc.*

Joint marketing and assay validation agreement

They will validate In-Cell Western cellular imaging assays on Li-Cor's Odyssey Infrared Imaging System using CST's anti- body reagents (6/1)

CombiMatrix Group (CMBX)

Axon Instrument Inc. (OTC BB:AXNIF)

Co-marketing relationship to jointly support sales of their products

The deal involves CombiMatrix's Custom- Array microarray platform and Axon's GenePix scanners (6/14)

Crucell NV (the Netherlands; CRXL) and DSM Biologics

Chiron Corp. (CHIR)

Chiron will use the PER.C6 cell line for development of recombinant monoclonal antibody products

Crucell and DSM will receive an up-front payment and annual maintenance fees; further terms were not disclosed (6/15)

Crucell NV (the Netherlands; CRXL) and DSM Biologics

Merus BV* (the Netherlands)

Merus will use the PER.C6 cell line for development of its Oligoclonics antibody technology

Crucell and DSM will receive an up-front payment and annual maintenance fees; further terms were not disclosed (6/10)

Crucell NV (the Netherlands; CRXL) and DSM Biologic

PanGenetics BV* (the Netherlands)

PanGenetics will use the PER.C6 cell line for preclinical manufacturing of recombinant monoclonal antibody products

Crucell and DSM will receive an up-front payment and annual maintenance fees; further terms were not disclosed (6/8)

DeCode Genetics Inc. (Iceland; DCGN)

Adventrx Pharmaceuticals Inc. (AMEX:ANX)

Thiovir, an oral prodrug of the antiviral foscarnet

DeCode began manufacturing the drug in preparation for Adventrx's IND filing for clinical trials (6/1)

Epoch Biosciences Inc. (EBIO)

Celera Dignostics (joint venture of Celera Genomics Group and Applied Biosystems Group)

Expanded license for incorporation of Epoch's minor groove binder and quencher into Celera's products for certain infectious diseases

The deal expands Celera's rights beyond the orginal deal; all other terms remain the same (5/19)

GeneGo Inc.*

Invitrogen Corp. (IVGN)

Invitrogen licensed biological pathways to add bioinformatics capabilities to its offerings

Further details and financial arrangements were not disclosed (6/1)

Meridian Bioscience Inc. (VIVO)

Viral Therapeutics Inc.*

Collaboration to support clinical and commercial development needs of biopharmaceutical partners

Meridian subsidiary Viral Antigens Inc. and VTI are combining resources to produce recombinant proteins, therapeutic antibodies and vaccines (6/3)

Morphotek Inc.*

Tanox Inc. (TNOX)

Tanox got rights to use SIP technology to develop mammalian cell line hosts for the manufacturing of antibodies

Morphotek under the nonexclusive deal will get an up-front payment and research fees, as well as potential milestones and royalties on sales of products manufactured using the cell lines (6/7)

ParAllele BioScience Inc. (AFFX)

Affymetrix Inc.*

They are offering early access to ParAllele's MegAllele genotyping reagents for use with Affymetrix GeneChip arrays

ParAllele will design assays and manufacture reagent kits and genotyping software under the nonexclusive deal; Affymetrix will market them with its arrays and instrumentation (5/19)

Pharmion Corp. (PHRM)

Lipomed AG* (Switzerland)

Lipomed was named exclusive distributor of Thalidomide Pharmion in Switzerland and Austria

Lipomed also will distribute Pharmion's Refludan and Vidaza in those countries; Lipomed will stop distributing its thalidomide formulation there, and Pharmion dropped its patent litigation (5/3)

Ovation Pharmaceuticals Inc.*

Paladin Labs Inc. (Canada; TSE:PLB)

Paladin acquired Canadian distribution rights to the epilepsy drugs Sabril and Frisium

Terms were not disclosed; Ovation acquired North American rights to the products from Aventis SA in March (5/27)

Qiagen NV (the Netherlands; QGENF)

Protedyne Corp.*

Deal to develop a sample preparation system for use in molecular diagnostics

The goal is to develop ultra-high- throughput nucleic acid purification procedures on Protedyne's BioCube Systems (6/14)

ViroLogic Inc. (VLGC)

Quest Diagnostics Inc. (NYSE:DGX)

Quest will make ViroLogic its preferred provider of HIV phenotypic resistance testing

Further terms of the expanded referral testing agreement were not disclosed (5/3)


Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments